2024
Sex differences in comorbid pain and opioid use disorder: A scoping review
DeVito E, Ameral V, Sofuoglu M. Sex differences in comorbid pain and opioid use disorder: A scoping review. British Journal Of Clinical Pharmacology 2024 PMID: 39168150, DOI: 10.1111/bcp.16218.Peer-Reviewed Original ResearchOpioid use disorderChronic painTreatment of opioid use disorderChronic opioid usePost hoc analysisPersistent painClinical courseOpioid useComorbid painSex/gender differencesOpioid misuseOpioidPainUse disorderHighest prevalencePost-hocOutcome variablesDisordersTreatmentHuman subjectsBiological underpinningsPsychosocial factorsTreatment effectsSex differencesSex
2020
Impulsivity across Substance Use Categories: Consideration of Sex/Gender
DeVito EE, Weinberger AH, Pang RD, Petersen N, Fagle T, Allen AM. Impulsivity across Substance Use Categories: Consideration of Sex/Gender. Current Behavioral Neuroscience Reports 2020, 7: 109-127. PMID: 33614396, PMCID: PMC7891462, DOI: 10.1007/s40473-020-00213-6.Peer-Reviewed Original ResearchSubstance use disordersUse disordersSubstance use groupSubstance use categoriesSubstance-using populationsHigh impulsivitySubstance use severityClinical severityUse of substancesTreatment outcomesInclusion criteriaSex/genderSubstance use behaviorsSex/gender differencesReviewThe goalUse severityRecent evidenceSeverityRange of substancesRole of impulsivityDisordersImpulsivityFemale individualsGender differencesCurrent body
2019
Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science 2019, 7: 1190-1206. PMID: 32042509, PMCID: PMC7009780, DOI: 10.1177/2167702619855659.Peer-Reviewed Original ResearchOpioid use disorderClinical featuresUse disordersHigher anhedonia scoresKey clinical featuresRate of participantsAnhedonia scoresOpioid-dependent sampleOpioid cravingOpioid useTreatment adherenceHealthy controlsSignificant anhedoniaPharmacological interventionsAssessment of anhedoniaMajority of studiesPotential targetAnhedoniaTreatmentTime courseDisordersSignificant knowledge gapsScoresPotential implicationsCritical needRandomized placebo-controlled trial of galantamine in individuals with cocaine use disorder
DeVito EE, Carroll KM, Babuscio T, Nich C, Sofuoglu M. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal Of Substance Use And Addiction Treatment 2019, 107: 29-37. PMID: 31757262, PMCID: PMC6918721, DOI: 10.1016/j.jsat.2019.08.009.Peer-Reviewed Original ResearchConceptsCocaine use disorderSignificant treatment group differencesUse disordersEfficacy of galantamineTreatment-seeking cocaine usersCurrent cocaine use disordersGroup differencesCocaine use outcomesSample of individualsTreatment group differencesComorbid opioid use disorderMethadone-maintained individualsMemory capacityAbstinent individualsCocaine useCognitive improvementCognitive outcomesCocaine use reductionCognitive functionUse outcomesCocaine usersGalantamine groupIndividualsDisordersInitial promise
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipants
2012
Impaired inhibitory control in ‘internet addiction disorder’: A functional magnetic resonance imaging study
Dong G, DeVito EE, Du X, Cui Z. Impaired inhibitory control in ‘internet addiction disorder’: A functional magnetic resonance imaging study. Psychiatry Research 2012, 203: 153-158. PMID: 22892351, PMCID: PMC3650485, DOI: 10.1016/j.pscychresns.2012.02.001.Peer-Reviewed Original ResearchConceptsIAD groupMagnetic resonance imaging studyPrevalent mental health concernAddiction disordersResonance imaging studyFunctional magnetic resonance imaging studyPosterior cingulate cortexMental health concernsImpaired inhibitory controlHealthy controlsHealthy peersInternet addiction disorderCingulate cortexImaging studiesHealth concernDisordersNeurobiological underpinningsInhibitory controlResponse inhibitionNeural correlatesResponse inhibition processesPotential heterogeneityPresent studyGroup
2008
Response to comments on ‘Methylphenidate improves response inhibition but not reflection impulsivity in children with attention deficit hyperactivity disorder (ADHD)’
DeVito E, Sahakian B. Response to comments on ‘Methylphenidate improves response inhibition but not reflection impulsivity in children with attention deficit hyperactivity disorder (ADHD)’. Psychopharmacology 2008, 203: 187-187. DOI: 10.1007/s00213-008-1383-5.Peer-Reviewed Original Research